Summary
The response to a single oral dose of 0.5 mg digoxin has been studied in eight patients, of whom four were hyperthyroid and four were hypothyroid, both before and after treatment for their thyroid dysfunction. The post-dose plasma digoxin levels were significantly lower in the hyperthyroid patients when they were thyrotoxic than when they became euthyroid. In only one hypothyroid patient was the post-dose plasma digoxin level significantly higher before treatment than it was after and in the others the digoxin values reached were either the same as, or lower than, before treatment. There was a significant correlation between the creatinine clearance and the urinary concentrations of digoxin and these both altered with change in thyroid status. Total urinary digoxin excretion did not change. Pharmacokinetic analysis suggested that digoxin was distributed in a way compatible with a two-compartment model and that the volume of the central compartment was high in thyrotoxic patients and low in hypothyroid patients. In both cases it reverted to a median value after treatment. It is recommended that plasma digoxin levels should be monitored in all patients with thyroid dysfunction who require therapeutic digoxin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Crookson, H.: The thyroid and the heart. Brit. Med. J.1959/I, 254
Frye, R.L., Braunwald, E.: Studies on digitalis III. The influence of triiodothyronine on digitalis requirements. circulation23, 376–382 (1961)
Conney, A.H., Garren, L.: Contrasting effects of thyroxine on zoxazolamine and hexobarbital metabolism. Biochem. Pharmacol.6, 257–262 (1968)
Kato, R., Takahashi, A.: Thyroid hormone and activities of drugmetabolising enzymes and electron transport systems of rat liver microsomes. Molec. Pharmacol.4, 109–120 (1968)
Crooks, J., Hedley, A.J., MacNee, C., Stevenson, L.H.: Changes in drug metabolising ability in thyroid disease. Brit. J. Pharmacol.49, 156P-157P (1973)
Eichelbaum, M., Bodem, G., Gugler, R., Schneider-deters, C., Dengler, H.J.: Influence of thyroid status on plasma half-life of antipyrine in man. N. Engl. J. Med.290, 1040–1042 (1974)
Doherty, J.E., Perkins, W.H.: Digoxin metabolism in hypo- and hyperthyroidism. Studies with tritiated digoxin in thyroid disease. Ann. Int. Med.64, 489–507 (1966)
Eickenbusch, W., Lahrtz, H., Seppelt, U., Van Zwieten, P.A.: Serum concentration and urinary excretion of3H-ouabain and3H-digitoxin in patients suffering from hyperthyroidism or hypothyroidism. Klin. Wschr.5, 270–275 (1970)
Croxson, M.S., Ibbertson, H.K.: Serum digoxin in patients with thyroid disease. Brit. Med. J.1975/3, 566–568
Gilfrich, H.J.: Untersuchungen zur Pharmakokinetik von Digoxin bei hyperthyreoten Patienten. Verh. der Dtsch. Ges. Inn. Med.82, 1726–1728 (1976)
Eichelbaum, M.: Drug Metabolism in Thyroid Disease. Clin. Pharmakokinetics1, 339–350 (1976)
Horn, D.B.: Unpublished data
Greenwood, H., Snedden, W., Hayward, R.P., Landon, J.: The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy. Clin. Chim. Acta62 (2), 213–224 (1975)
Sedman A.J. and Wagner, J.G.: A decision-making Pharmacokinetic computer program. Publication Distribution Service, 615 East University Avenue, Ann Arbor, Michigan 48106, USA (1974)
Metzler, C.M.: Nonlin. The Upjohn Company Technical Report 7292/69/7292/005. Kalamazoo, Michigan, USA (1969)
Buccino, R.A., Spann, J.F. Jnr., Pool, P.E.: Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J. Clin. Invest.46, 1669–1682 (1967)
Peacock, W.F., Moran, N.C.: Influence of thyroid state on positive inotropic effect of ouabain on isolated rat ventriclestrips. Proc. Soc. Exp. Biol. Med.113, 526–530 (1963)
Morrow, D.H., Gaffney, T.E., Braunwald, E.: Studies on digitalis VII. Influence of hyper- and hypothyroidism on the myocardial response to ouabain. J. Pharmacol. Exp. Ther.140, 324–328 (1963)
Kalk, W.J., Lawrence, J.R., Ratcliffe, W.A., Sumner, D.J., Whiting, B.: Digoxin pharmacokinetics in hyperthyroidism. Brit. J. Clin. Pharmacol.3, 954P (1976)
Aronson, J.K., Grahame-Smith, D.G.: Digoxin therapy: textbooks, theory and practice. Brit. J. Clin. Pharmacol.3, 639–648 (1976)
Bloom, P.M., Nelp, W.B.: Relationship of the excretion of tritiated digoxin to renal function. Amer. J. Med. Sci.251, 133–144 (1966)
Sumner, D.J., Russell, A.J., Whiting, B.: Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications. Brit. J. Clin. Pharmacol.3, 221–229 (1976)
Bradley, S.E., Stephen, F., Coelho, J.B., Reville, P.: The thyroid and the kidney. Kidney Internat.6, 346–365 (1974)
Doherty, J.E., Ferrell, C.B., Towbin, E.J.: Localisation of the renal excretion of tritiated digoxin. Amer. J. Med. Sci.258, 181–189 (1968)
Steiness, E.: Renal tubular secretion of digoxin. Circulation50, 103–107 (1974)
Hartmann, C.R., Klaassen, C.D., Huffman, D.H.: The biliary excretion of digoxin and metabolites in hyperthyroid rats. Clin. Res.23, 220A (1975)
Kemp, J.R., Greenblatt, D.J., Jusko, W.J., Smith, T.W., Koch-weser, J.: Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J. Pharmacokin. Biopharm.3, 181–192 (1975)
Hall, W.H., Doherty, J.E.: Tritiated digoxin XVI. Gastric absorption. Digest. Dis.16, 903–908 (1971)
Thomas, F.B., Caldwell, J.W., Greenberger, N.J.: Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann. Intern. Med.78, 669–675 (1973)
Watters, K., Tomkin, G.H.: Serum digoxin in patients with thyroid disease. Brit. Med. J.1975/4, 102
Evered, D.C.: The binding of digoxin by the serum proteins. Europ. J. Pharmacol.18, 236–244 (1972)
Smith, T.W., Haber, E.: Digitalis (Third of four parts). Pharmacokinetics and bioavailability. N. Engl. J. Med.289, 1063–1072 (1973)
Lindsay, R., Parker, J.L.W.: Rat hepatic sodium plus postassium iondependent adenosine triphosphatase after treatment with digoxin and thyroxine. Clin. Sci. Mol. Med.50, 329–332 (1976)
Chamberlain, D.A., White, R.J., Howard, M.R., Smith, T.W.: Plasma digoxin concentrations in patients with atrial fibrillation. Brit. Med. J.1970/3, 429–432
Parker, J.L.W., Lawson, D.H.: Death from thyrotoxicosis. Lancet1973/II, 894–895
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shenfield, G.M., Thompson, J. & Horn, D.B. Plasma and urinary digoxin in thyroid dysfunction. Eur J Clin Pharmacol 12, 437–443 (1977). https://doi.org/10.1007/BF00561063
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561063